Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-29
2008-01-29
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S254000
Reexamination Certificate
active
07323483
ABSTRACT:
The present invention provides processes for the preparation of substituted naphthylindole derivatives that can be used as inhibitors of plasminogen activator inhibitor-1(PAI-1). In certain embodiments of the invention, the processes involve reactions that include one or more of an Oppenauer oxidation, a Fischer indole synthesis, a methyl ether cleavage, or coupling a substituted methyltetrazole with a substituted naphthol.
REFERENCES:
patent: 5151435 (1992-09-01), Bagley et al.
patent: 6800654 (2004-10-01), Mayer et al.
patent: 6939886 (2005-09-01), Mayer et al.
patent: 2002/0198411 (2002-12-01), Tanikawa et al.
patent: 0 416 609 (1991-03-01), None
patent: 0 508 723 (1992-10-01), None
patent: 0 512 570 (1992-11-01), None
patent: 0 655 439 (1995-05-01), None
patent: WO 94/26738 (1994-11-01), None
patent: WO 95/10513 (1995-04-01), None
patent: WO 96/21656 (1996-07-01), None
patent: WO 97/09308 (1997-03-01), None
patent: WO 98/08818 (1998-03-01), None
patent: 03/000649 (2003-01-01), None
patent: 03/000684 (2003-01-01), None
Ooi, T., et al., “Practical Oppenauer (OPP) Oxidation of Alcohols with a Modified Aluminum Catalyst,”Organic Letters,2002, 4, 2669-2672.
Smith, M.B. and March, J.,Advanced Organic Chemistry,Wiley 5thed. 2001, pp. 496, 503, 520, and 528.
Aznar, J. et al., “Role of Plasminogen Activator Inhibitor Type 1 in the Pathogenesis of Coronary Artery Diseases,”Haemostasis24: 243-251 (1994).
Biemond, B.J. et al., “Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis,”Circulation,91: 1175-1181 (1995).
Carmeliet, P. et al., “Plasminogen Activator Inhibitor -1 Gene-deficient Mice,”Journal of Clinical Investigation,92: 2756-2760 (Dec. 1993).
Daci, E. et al., “Mice Lacking the Plasminogen Activator Inhibitor 1 are Protected from Trabecular Bone Loss Induced by Estrogen Deficiency,”Journal of Bone and Mineral Research,15(8):1510-1516 (Nov. 8, 2000).
Krishnamurti, C. et al., “Plasminogen Activator Inhibitor: A Regulator of Ancrod-Induced Fibrin Deposition in Rabbits,”Blood,69(3): 798-803 (Mar. 1987).
Levi, M. et al., “Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Experimental Thrombosis,”Circulation85, 305-312 (1992).
Nordt, T. K. et al., “Differential Regulation by Troglitazone of Plasminogen Activator Inhibitor Type 1 in Human Hepatic and Vascular Cells,”Journal of Clinical Endocrinology and Metabolism,85(4):1563-1568 (2000).
Reilly, C. et al., “Both Circulating and Clot-Bound Plasminogen Activator-1 Inhibit Endogenous Fibrinolysis in the Rat,”Arteriosclerosis and Thrombosis,11(5): 1276-1286 (Sep./Oct. 1991).
Rocha, E. et al., “The Relationship Between Impaired Fibrinolysis and Coronary Heart Disease,”Fibrinolysis,8: 294-303 (1994).
Aznar et al., “role of Plasminogen Activator Inhibitor Type 1 in the Pathogenesis of Coronary Artery Diseases,”Haemostatis,1994, 24, 243-251.
Biemond et al., “Thyrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis: Effects of a Plasminogen Activator Inhibitor Type 1-Neutralizing Monoclonal Antibody,”Circulation,1995, 91(4), 1175-1181.
Carmeliet et al., “Plasminogen Activator Inhibitor-1 Gene-deficient Mice; II. Effects of hemostasis, Thrombosis, and Thrombolysis,”Journal of Clinical Invest.,1993, 92, 2756-2760.
Daci et al., “Mice Lacking the Plasminogen Activator Inhibitor 1 Are Protected from Trabecular Bone Loss Induced by Estrogen Deficiency,”Journal of Bone&Mineral Research,2000, 15(8), 1510-1516.
Guzzo, P.R. et al., “Synthesis of a conformationally constrained threonin-valine dipeptide mimetic: design of potential inhibitor of plasminogen activator inhibitor-1,”Tetrahedron Letters,2002, 43(1), 41-42.
Krishnamurti et al., “Plasminogen Activator Inhibitor: A Regulator of Ancrod-Induced Fibrin Deposition in Rabbits,”Blood,1987, 69(3), 798-803.
Levi et al., “Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Extension in Models of Experimental Thrombosis,”Circulaiton,1992, 85(1), 305-312.
Nordt et al., “Differential Regulation by Troglitazone of Plasminogen Activator Inhibitor Type 1 in Human Hepatic and Vascular Cells,”The Journal of Clinical Endocrinology&Metabolism,2000, 85(4), 1563-1568.
Reilly et al., “Both Circulating and Clot-Bound Plasminogen Activator Inhibitor-1 Inhibit Endogenous Fibrolysis in the Rat,”Arteriosclerosis&Thrombosis,1991, 11, 1276-1286.
Rocha et al., “The Relationship Between Impaired Fribinolysis and Coronary Heart Disease: a Role for PAI-1,”Fibrinolysis,1994, 8, 294-303.
Dragan Vladimir A.
Helom Jean Louise
McMahon Wayne G.
Potoski John Richard
Shi Xinxu
Anderson Rebecca
Ng Mabel
Wyeth
Young Shawquia
LandOfFree
Processes and compounds for the preparation of substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Processes and compounds for the preparation of substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processes and compounds for the preparation of substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2751367